Search Results 131-140 of 15092 for infliximab

  1. Ustekinumab-auub (intravenous route, subcutaneous route) - Side effects & dosage - Mayo Clinic

    Cyclosporine; Dengue Tetravalent Vaccine, Live; Ebola Zaire Vaccine, Live; Infliximab; Influenza Virus Vaccine, Live; Measles Virus Vaccine, Live; Mumps Virus ...

  2. Clinical Trials - TD-1473 for Active Ulcerative Colitis (UC)

    ... infliximab, golimumab, etanercept, or certolizumab within the 60 days prior to Day 1, c) intravenous corticosteroids within the 14 days prior to Day 1, d ...

  3. Publications - C. Scott Collins, M.D. - Mayo Clinic

    ... infliximab. BMJ Case Rep. 2013 Mar 15; 2013. View PubMed; Feely MA, Collins CS, Daniels PR, Kebede EB, Jatoi A, Mauck KF. Preoperative testing before ...

  4. Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease - Mayo Clinic

    Maintenance monotherapy: infliximab (at least 8 every 8 weeks), golilumumab (at least monthly), adalilumab (at least every 2 weeks), or certolizumab (at least ...

  5. A Study to Assess the Effectiveness and Safety of Golimumab in Pediatric Participants With Moderately-to-Severely Active Ulcerative Colitis - Mayo Clinic

    Contraindications to the use of golimumab or infliximab or anti-tumor necrosis factor (TNF-alpha) therapy per local prescribing information. Participating ...

  6. A Study to Evaluate the Safety and Effectiveness of Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients with Crohn's Disease - Mayo Clinic

    Infliximab: at least 14 weeks treatment at the approved doses for induction and/or maintenance in Crohn´s disease prior to screening for the study. For ...

  7. A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis - Mayo Clinic

    Infliximab, certolizumab, golimumab, ABA or adalimumab within ≤ 8 weeks; Anakinra within ≤ 1 week. Pulmonary disease with FVC ≤ 50% of predicted, or DLCO ...

  8. Insights into IBD genetics - Mayo Clinic

    Double your impact on cancer! ... Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge. Give Now.

  9. Brodalumab (subcutaneous route) - Side effects & dosage - Mayo Clinic

    Haloperidol; Infliximab; Influenza Virus Vaccine, Live; Measles Virus Vaccine, Live; Mumps Virus Vaccine, Live; Poliovirus Vaccine, Live; Roflumilast; Rotavirus ...

  10. Encorafenib (oral route) - Mayo Clinic

    Encorafenib is also used in combination with binimetinib to treat non-small cell lung cancer (NSCLC) that has spread in patients who have BRAF V600E mutations.